ljpc موعدنا 20 من الشهر

[راعي العين]

ljpc موعدنا تياريخ 20 من هالشهر والهدف دولار ان شاءالله

 

[مسااااهم]

هل عليها خبر او شنو السالفه وليه محدد هذا التاريخ بالذات

ارجوا التوضيح لو تكرمت

 

[girgish1]

كن حذرا اخي العزيز.

التقرير الاخير ليس غير جيد وحسب بل سئ للغاية تماما وأي إرتفاع هو غير مبرر وطريقه مثلى للتصريف
http://biz.yahoo.com/e/090612/ljpc8-k.html

والله أعلى وأعلم

 

[girgish1]

هذا قصده

هل عليها خبر او شنو السالفه وليه محدد هذا التاريخ بالذات

ارجوا التوضيح لو تكرمت

Human Genome will be releasing results from the Benlysta phase III study in lupus patients before the opening bell on Monday, July 20.

A chorus of analysts says the study is going to fail.

"We continue to believe the probability that Lymphostat-B succeeds is extremely low, wrote an analyst at Lazard Capital Markets on Tuesday, tacking a sell rating and a $1 price target to the stock.

وهذا موجود يالتقرير الاخير

In February 2009, La Jolla Pharmaceutical Company (the "Company") announced that an Independent Data Monitoring Board for the Riquent? Phase 3 ASPEN study had completed its review of the first interim efficacy analysis of Riquent and determined that continuing the study was futile. Based on these results, the Company immediately discontinued the Riquent Phase 3 ASPEN study and the development of Riquent. The Company had previously devoted substantially all of its research, development and clinical efforts and financial resources toward the development of Riquent. In connection with the termination of the clinical trials for Riquent, the Company subsequently initiated steps to significantly reduce its operating costs, including the termination of 75 employees, which was effected in April 2009, and ceased all Riquent manufacturing and regulatory activities.

والشركة لا تستطيع بيع بعض الاصول او الشركة كلها بسبب قضية مرفوعه على الشركة
BioMarin Lawsuit

On May 22, 2009, the Company and its directors were sued by BioMarin Pharmaceutical Company ("BioMarin") in California Superior Court, alleging breach of contract, breach of covenant of good faith and fair dealing, and breach of fiduciary duty. BioMarin, which had been the Company's development partner for Riquent, sued to force the Company to accelerate the timing for the registration of approximately 10 million shares of restricted common stock that BioMarin had purchased from the Company when entering into the collaboration for Riquent in January 2009. Additionally, BioMarin seeks to recover damages for any loss it may suffer due to the alleged breach. The Company believes these claims are wholly without merit.

BioMarin sought a Temporary Restraining Order and a Preliminary Injunction compelling the Company to effect the registration of these shares notwithstanding what the Company believes are longer time periods afforded under the relevant agreement. Since filing this lawsuit, the Court has twice denied BioMarin the relief it sought. Most recently, on June 2, 2009, BioMarin's motion for a Preliminary Injunction was denied by the Court, with the Court finding that BioMarin had not demonstrated that it was likely to succeed on the merits of its suit and that the contract did not require the Company to register the shares in the accelerated time period as demanded by BioMarin. Notwithstanding the Court's findings against BioMarin, BioMarin has refused to drop its claims without a guaranteed price at which it would be able to ultimately sell its stock. Accordingly, the lawsuit remains pending, although the Company will be seeking to have the lawsuit dismissed and will bring any viable counterclaims that it may have.

والله أعلى وأعلم

 

[مسااااهم]

جزاك الله الف خير عزيزي

 

[راعي العين]

مثل ماوعتكم سهم hgsi يداول الحين 9 دورلا من 3 قفز ان شاءالله سهمنا دورلا مبررررررررررررروك

 

[راعي العين]

علما الاسهم الحيويه في السوق الامريكي اربع شركات فقط تتفاعل كلها

 

[girgish1]

الساعة المباركة

مثل ماوعتكم سهم hgsi يداول الحين 9 دورلا من 3 قفز ان شاءالله سهمنا دورلا مبررررررررررررروك

دائما وابدا نتمنى الخير للجميع

وإن شاء الله ياصل 10 دولار....انا واعوذ بالله من انا راح اكون اول واحد يفرح لكم. ولكن لابد من التعامل مع الحقائق لان هذا سوق ما يرحم والحذر واجب

بالتوفيق للجميع والله يرزقنا وياكم والمسلمين اجمعين.

 

[بوشعيب]

مثل ماوعتكم سهم hgsi يداول الحين 9 دورلا من 3 قفز ان شاءالله سهمنا دورلا مبررررررررررررروك

11 دولار مبروووووووووك

 

[راعي العين]

الحمدالله كل الاسهم اللي وصيت عليها اترفعت بفضل ربي حتى هالسهم الغبي والله في خاطري اقوله تو الناس لو مارتفعت وصيت عليه سعره بلاش ومكسبه كبير 10 سنت تعادل 50 سنت في اي سهم سعر عالي هالقصد من التوصيه ورتفع بس تخر اشوي الحبيب

 

[راعي العين]

human genome will be releasing results from the benlysta phase iii study in lupus patients before the opening bell on monday, july 20.

A chorus of analysts says the study is going to fail.

"we continue to believe the probability that lymphostat-b succeeds is extremely low, wrote an analyst at lazard capital markets on tuesday, tacking a sell rating and a $1 price target to the stock.

وهذا موجود يالتقرير الاخير

in february 2009, la jolla pharmaceutical company (the "company") announced that an independent data monitoring board for the riquent? Phase 3 aspen study had completed its review of the first interim efficacy analysis of riquent and determined that continuing the study was futile. Based on these results, the company immediately discontinued the riquent phase 3 aspen study and the development of riquent. The company had previously devoted substantially all of its research, development and clinical efforts and financial resources toward the development of riquent. In connection with the termination of the clinical trials for riquent, the company subsequently initiated steps to significantly reduce its operating costs, including the termination of 75 employees, which was effected in april 2009, and ceased all riquent manufacturing and regulatory activities.

والشركة لا تستطيع بيع بعض الاصول او الشركة كلها بسبب قضية مرفوعه على الشركة
biomarin lawsuit

on may 22, 2009, the company and its directors were sued by biomarin pharmaceutical company ("biomarin") in california superior court, alleging breach of contract, breach of covenant of good faith and fair dealing, and breach of fiduciary duty. Biomarin, which had been the company's development partner for riquent, sued to force the company to accelerate the timing for the registration of approximately 10 million shares of restricted common stock that biomarin had purchased from the company when entering into the collaboration for riquent in january 2009. Additionally, biomarin seeks to recover damages for any loss it may suffer due to the alleged breach. The company believes these claims are wholly without merit.

Biomarin sought a temporary restraining order and a preliminary injunction compelling the company to effect the registration of these shares notwithstanding what the company believes are longer time periods afforded under the relevant agreement. Since filing this lawsuit, the court has twice denied biomarin the relief it sought. Most recently, on june 2, 2009, biomarin's motion for a preliminary injunction was denied by the court, with the court finding that biomarin had not demonstrated that it was likely to succeed on the merits of its suit and that the contract did not require the company to register the shares in the accelerated time period as demanded by biomarin. Notwithstanding the court's findings against biomarin, biomarin has refused to drop its claims without a guaranteed price at which it would be able to ultimately sell its stock. Accordingly, the lawsuit remains pending, although the company will be seeking to have the lawsuit dismissed and will bring any viable counterclaims that it may have.

والله أعلى وأعلم

استعيلت ياخوي الشركة كسبة الدعوه من المحكمه وتم الفراج عن جميع الاصول لكن زعل صاحب الشركة من الوضع اللي صارله وطلب نقل شركتة والاسهم من الموشر

 

[راعي العين]

وتمت الموافقة على نقلها من السوق العالمية لسوق المال ، وذلك اعتبارا من بدء العمل على 21 يوليو 2009 ، وقائمة للشركة عام الأسهم نقل إلى سوق المال. على الرغم من التغيير في قائمة لسوق المال والبورصة لا يزال يتم تداول تحت الرمز "ljpc".

 

[khaled76]

60% بالتوفيق انشالله

 

[q8_kwt]

راعي العين هل في خبر عن تقسيم السهم ... لان سعر السهم مغري و احتمال ادخل عليه

 

[راعي العين]

والله السهم مغري ومغري وصار ماعنده مشكله بعد الافراج كانت هاي المشكله وانتهت وحاس لعبه لصعود اسهم حيويه ثانيه والله اعلم وابين من زعل ادارة الشركة السهم فيه الخير بس عن التقسم ماتعمقت في الموظوع مرهق اشوي بشوف وبرد عليك

 

[q8_kwt]

اوكي نسولف على راحتنا بعدين

 

[q8_kwt]

ان شاء الله نشوف السهم صاعد هذا الاسبوع

 

[q8_kwt]

للرفع

 

[راعي العين]

ماشي جديد بس السهم جيد لمدى طويل وراح اشوفه اخر السنه

 

[مشعل المناور]

في أخبار جديده؟؟؟

السهم لازال في نزول